Table 2 Characteristics and assessment of the PAP cohort

Age

41 ± 12.8 (yrs)

Gender

Male

52

71

Female

21

29

Smoking status

Current

16

22

Former

33

45

Never

24

33

Exposures ¹

26

36

Symptoms at enrollment

Symptomatic

69

95

dyspnea²

49

67

cough

23

31

fever

8

11

sputum production

1

1

Asymptomatic

4

5

Diagnostic procedures ³

69

HR CT Scan

51

74

Biopsy

41

56

BAL

32

46

GMAbs⁴

31

45

Infection at enrollment ⁴

14

19

Lung Function ⁵

FVC

57

75.50 ± 21.1 (% predicted)

FEV₁

57

77.77 ± 18.49 (% predicted)

TLC

57

75.38 ± 14.77 (% predicted)

DLCO

57

51.83 ±17.90 (% predicted)

PaO2

57

64.46 ± 14.17 (mm Hg)

ΔA-aO2

57

41.44 ± 16.25 (mm Hg)

Exercise Sat.O2

57

-4.27% ± 1.93

Biomarkers ⁶

Cyfra 21-1

26

12.8 ± 14.6 (ng/mL) (nv: 0.0-3.3)

CEA

27

13.4 ± 13.4 (ng/mL) (nv: 0.0-5.0)

NSE

23

20.04 ± 6.9 (ng/mL) (nv: 0.0-15.0)

LDH

57

550.3 ± 248 (U/L) (nv: 230-460)

GMAbs

31

184.1 ± 175 (μg/ml) (nv < 3)

DSS ⁷

39

1

2

5

2

12

31

3

13

33

4

4

10

5

8

21